OPKO Health Outlines $560M-$585M Revenue Guidance for 2026 and Plans to Initiate MDX3001 Clinical Trials by End of 2026
During the second quarter, OPKO Health (NASDAQ: OPK) made progress in improving operating efficiency and profitability while advancing its product pipeline. The company outlined revenue guidance for 2026 between $560 million to $585 million. Additionally, it plans to initiate clinical trials for MDX3001 by the end of 2026 or early 2027. Dr. Phillip Frost, Chairman and CEO, highlighted these developments in a Q2 2026 management update call. The guidance reflects OPKO's strategic focus on both operational improvements and pipeline advancements as it moves forward with its development programs.
